News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,893 Results
Type
Article (40061)
Company Profile (250)
Press Release (664581)
Multimedia
Podcasts (62)
Webinars (14)
Section
Business (204285)
Career Advice (2011)
Deals (35457)
Drug Delivery (95)
Drug Development (81158)
Employer Resources (172)
FDA (16250)
Job Trends (14887)
News (345528)
Policy (32607)
Tag
Academia (2556)
Accelerated approval (9)
Adcomms (22)
Allergies (95)
Alliances (49570)
ALS (108)
Alzheimer's disease (1441)
Antibody-drug conjugate (ADC) (151)
Approvals (16246)
Artificial intelligence (311)
Autoimmune disease (28)
Automation (18)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (121)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (33)
Breast cancer (365)
Cancer (2859)
Cardiovascular disease (212)
Career advice (1681)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (497)
Cervical cancer (22)
Clinical research (66860)
Collaboration (1011)
Company closure (3)
Compensation (686)
Complete response letters (22)
COVID-19 (2625)
CRISPR (56)
C-suite (324)
Cystic fibrosis (112)
Data (2992)
Decentralized trials (2)
Denatured (23)
Depression (60)
Diabetes (346)
Diagnostics (6423)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (137)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (124)
Earnings (87456)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113740)
Executive appointments (845)
FDA (17895)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (928)
Gene editing (129)
Generative AI (22)
Gene therapy (372)
GLP-1 (780)
Government (4502)
Grass and pollen (4)
Guidances (181)
Healthcare (18840)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (146)
Immuno-oncology (8)
Indications (39)
Infectious disease (2797)
Inflammatory bowel disease (148)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (119)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (492)
Leadership (18)
Legal (7929)
Liver cancer (79)
Longevity (11)
Lung cancer (399)
Lymphoma (208)
Machine learning (11)
Management (58)
Manufacturing (383)
MASH (90)
Medical device (13462)
Medtech (13467)
Mergers & acquisitions (19581)
Metabolic disorders (847)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2116)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (427)
Opinion (219)
Ovarian cancer (101)
Pain (105)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (296)
Patient recruitment (163)
Peanut (50)
People (57686)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20830)
Phase II (29448)
Phase III (21924)
Pipeline (1626)
Policy (199)
Postmarket research (2563)
Preclinical (8870)
Press Release (64)
Prostate cancer (140)
Psychedelics (36)
Radiopharmaceuticals (253)
Rare diseases (457)
Real estate (5917)
Recruiting (66)
Regulatory (22626)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (156)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3587)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (37)
Vaccines (778)
Venture capital (53)
Weight loss (256)
Women's health (47)
Worklife (16)
Date
Today (78)
Last 7 days (361)
Last 30 days (1884)
Last 365 days (31205)
2025 (16733)
2024 (35223)
2023 (40083)
2022 (51175)
2021 (55711)
2020 (54085)
2019 (46541)
2018 (35018)
2017 (32126)
2016 (31488)
2015 (37555)
2014 (31318)
2013 (26345)
2012 (28571)
2011 (29263)
2010 (27329)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (243)
Arkansas (13)
Asia (38204)
Australia (6232)
California (7430)
Canada (2357)
China (669)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82107)
Florida (1116)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (636)
India (26)
Indiana (361)
Iowa (16)
Japan (227)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1020)
Massachusetts (5518)
Michigan (246)
Minnesota (449)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2070)
New Mexico (28)
New York (2082)
North Carolina (1079)
North Dakota (8)
Northern California (3272)
Ohio (235)
Oklahoma (16)
Oregon (34)
Pennsylvania (1610)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2778)
Tennessee (126)
Texas (1122)
United States (27523)
Utah (219)
Virginia (184)
Washington D.C. (72)
Washington State (631)
West Virginia (4)
Wisconsin (66)
704,893 Results for "exelixis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Cancer
Exelixis Beats Bayer in Colorectal Cancer as Zanzalintinib Delivers ‘First Pivotal Success’
In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug candidate as a successor to cabozantinib, which is set to lose patent exclusivity in 2030.
June 23, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
July 14, 2025
·
1 min read
Pipeline
Exelixis Looks to Next-Gen Cancer Drug as Cabometyx Underwhelms Again
Exelixis’ next-generation tyrosine kinase inhibitor zanzalintinib is being tested for colorectal cancer, renal cell carcinoma and head-and-neck cancer, with several readouts slated for the second half of 2025.
February 19, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May 2025
May 8, 2025
·
1 min read
Press Releases
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
·
19 min read
Press Releases
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
June 20, 2025
·
17 min read
Press Releases
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
April 29, 2025
·
1 min read
Press Releases
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
June 23, 2025
·
7 min read
Press Releases
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
February 14, 2025
·
1 min read
Biotech Bay
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May 2024
Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May.
May 7, 2024
·
2 min read
1 of 70,490
Next
